According to an SEC Form D filed on September 2, 2010, Humacyte has raised $12 million in a private placement. That means Ms. Cox -- at this current development stage company, presides over about eight-one-hundredths of one percent of the asset-portfolio she last presided over -- at legacy Schering-Plough. That some come-down ($12 million/$15 billion), no?
Here is some of a local Durham, NC paper's take on it, tonight -- do go read it all, though:
. . . .Duke University spinoff Humacyte Inc., on Tuesday announced the appointment of Carrie S. Cox as the company’s new chief executive officer, effective September 20, 2010.
She will also assume a position on the board of the developmental stage firm. . . .
The Durham-based firm was founded in late 2004 to perfect a process using human cells to make artificial blood vessels capable of being transplanted into patients suffering from kidney failure and other ailments. . . .
Artifical blood vessels, you say? That will be a very tough nut to crack -- and especially so -- with only $12 million in the bank.
To help put it into perspective here, the company has, in market cap, less than one-fifth of Ms. Cox's all-in golden parachute value -- from old Schering-Plough (with Merck stock sitting at about $35 on the NYSE, tonight). Wow.